March 2025 FDA Recall Drug by Chattem Inc (D-0362-2025 - CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit)

This Class II drug recall was voluntarily initiated by Chattem Inc on March 26, 2025 for the product Drug. The FDA reported the reason for recall as cgmp deviations; detection of nitrosamine drug substance-related impurities (ndsri), n-nitroso-desmethyl-diphenhydramine (n-dph), above the fda recommended intake limit. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0362-2025

Reason for Recall
CGMP Deviations; detection of Nitrosamine Drug Substance-Related Impurities (NDSRI), N-nitroso-desmethyl-diphenhydramine (n-dph), above the FDA Recommended Intake Limit
Initiated
03-26-2025
Reported
04-23-2025
Quantity
129,240 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Unisom, SleepMinis, Diphenhydramine HCl, Mini-Capsules, 25 mg, 60 Mini-Capsules bottles, Dist. by Chattem, Inc., P.O. Box 2219, Chattanooga, TN 37409-0219, USA, UPC 0 41167 00670 2

Batch or Lot Expiration Information

Lot# LOT 22L603, EXP: Oct 2025; LOT 378999, EXP: Feb 2027